Colossal Biosciences funding rounds & valuation history
Colossal Biosciences, the Dallas de-extinction and conservation-genetics company. Funding from the Series A (Mar 2022) to the Series C extension (Sep 2025) plus later status rows, sourced to TechCrunch, Colossal, Crunchbase News, Observer and Axios Pro.
Round history
Newest first. Dashed badges and striped rows are not closed transactions. “—” means the source does not disclose the figure or it cannot be computed on the same basis; see the note in each row.
| Date | Status | Round | Amount | Lead / buyer | Valuation | Val. ÷ run-rate | Source |
|---|---|---|---|---|---|---|---|
Reported talks |
Reported raise at $25B–$26B (TWG-led)Narrows the July 2026 reported range; not closed. |
Not reported |
—Not disclosed |
$25B–$26B (reported)Reported talks (Axios Pro); CSV cells empty |
—Not disclosedTalks-stage or discussed figure; no multiple |
||
Reported talks |
Reported raise at $20B–$30BAxios later reported (30 Sep 2026) that TWG is expected to lead the round; not closed in the sources read. |
Not reported |
—Not disclosed |
$20B–$30B (reported)Reported talks (Axios via TechCrunch); CSV cells empty |
—Not disclosedTalks-stage or discussed figure; no multiple |
||
Closed round |
Series C extensionExtension of the Jan 2025 Series C, announced with Colossal’s dodo research update. |
$120M |
—Not disclosedWith: U.S. Innovative Technology Fund, Peter Jackson, Bob Nelson and others |
Over $10.3BLower bound (Observer: valuation “now tops $10.3 billion”) |
—Not disclosedNo run-rate stated in the announcement |
||
Closed round |
Series CTotal raised $435M after this round (Colossal). A $120M extension (Sep 2025) was announced via Business Wire but could not be fetched for verification, so it is not a row. |
$200M |
TWG Global |
$10.2BValuation stated by Colossal6.80× vs prior closed |
—Not disclosedNo run-rate stated in the announcement |
||
Closed round |
Series BMonth only. Led by Thomas Tull’s US Innovative Technology Fund (Crunchbase News). |
$150M |
US Innovative Technology Fund |
$1.5B (reported)Reported valuation (TechCrunch, 2025) |
—Not disclosedNo run-rate stated in the announcement |
||
Closed round |
Series A |
$60M |
—Not disclosed |
Not disclosedNo company valuation stated by the source |
—Not disclosedNo run-rate stated in the announcement |
Valuation at each closed round
Valuations as stated or reported at each closed round with a disclosed figure; talks, tenders and filings are not plotted.
Sources: TechCrunch, Colossal, Crunchbase News, Observer. US$ billions, linear scale.
Timeline
Each round and share sale, oldest first.
- 9 Mar 2022 · Closed
Series A: $60M.
- Jan 2023 · Closed
Series B: $150M at $1.5B (reported) led by US Innovative Technology Fund.
- 15 Jan 2025 · Closed
Series C: $200M at $10.2B led by TWG Global.
- 17 Sep 2025 · Closed
Series C extension: $120M at Over $10.3B.
- 20 Jul 2026 · Talks
Reported raise at $20B–$30B: Not reported.
- 30 Sep 2026 · Talks
Reported raise at $25B–$26B (TWG-led): Not reported.
Cite this dataset
Free to quote with a link back. Copy this citation:
Colossal Biosciences Funding Rounds & Valuation History. Private Valuation & Funding Round Tracker, GrowthNavigateFunding.net, updated 13 Nov 2026. https://growthnavigatefunding.net/funding/colossal-biosciences/
Download the data
The same 6 rows as the table: numeric US$ columns, empty cells where a figure is not disclosed, and a source URL for every row.
- File
colossal-biosciences-rounds.csv(UTF-8, comma-separated)- Stable URL
https://growthnavigatefunding.net/wp-content/uploads/2026/11/colossal-biosciences-rounds.csv- Columns
id,date,date_precision,status,transaction_type,round,amount_usd_low,amount_usd_high,lead_or_buyer,co_leads,valuation_usd_low,valuation_usd_high,valuation_basis,valuation_to_run_rate_multiple,multiple_bound,multiple_basis,step_up_vs_prior_closed,price_per_share_usd_low,price_per_share_usd_high,shares,source,source_url,other_source_urls,notes,last_updated- Updated
- (IST)
Methodology & status definitions
How each row is labelled and calculated.
Closed round
A primary round announced by the company or confirmed in the press, bringing new money to the company.
Reported talks
A raise reported by the press as under discussion and not confirmed as closed. Not charted, not the last-closed valuation; no step-up or multiple.
Valuation ÷ run-rate
Post-money valuation ÷ the run-rate the company stated in that announcement (GNF calc.). Where the run-rate is “crossed” or “over” a figure, the multiple is shown as “under X×”. No row qualifies here unless shown, so no multiple is invented.
What is not a separate row
Seed (2021); the UAE’s reported $60M investment; spin-outs (Form Bio, Breaking, Astromech).
Updates & corrections
This page stays at one address and is updated in place; the “Last updated” date above drives the citation and the dataset metadata. Corrections: hello@growthnavigatefunding.net. Informational only; not investment advice.
Changelog
- : Dataset first compiled (batch 3, not yet published).
Sources
- TechCrunch: Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation, 20 Jul 2026
- Colossal: Colossal Biosciences Raises $200M Series C Round, Jan 2025
- TechCrunch: Colossal Biosciences raises $200M at $10.2B valuation…, 15 Jan 2025
- Crunchbase News: De-Extinction Startup Colossal Biosciences Hits Decacorn Status After $200M Raise, 15 Jan 2025
- TechCrunch: Colossal grabs $60 million Series A for moonshot mammoth project, 9 Mar 2022
- Observer: The $10B Startup Behind the Revived Dire Wolf Reports Another Breakthrough, 17 Sep 2025
- Axios Pro: Scoop: Mark Walter’s TWG expected to lead Colossal’s new round, 30 Sep 2026